Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in HRR-mutated metastatic castration-sensitive prostate cancer
MOH_2020-10-01_009368Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of niraparib, abiraterone and prednisone in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to cancer worsening. Started Aug 2020; status: active, not recruiting.
02
Drugs
niraparibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2020-10-01_009368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-01_009368.